Viridian Other Current Assets from 2010 to 2024
| VRDN Stock | USD 24.26 0.47 1.98% |
Other Current Assets | First Reported 2013-12-31 | Previous Quarter 13.5 M | Current Value 10.3 M | Quarterly Volatility 3.4 M |
Check Viridian Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Viridian Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 1.9 M or Selling General Administrative of 99.7 M, as well as many indicators such as Price To Sales Ratio of 3.3 K, Dividend Yield of 0.0014 or PTB Ratio of 3.95. Viridian financial statements analysis is a perfect complement when working with Viridian Therapeutics Valuation or Volatility modules.
Viridian | Other Current Assets |
Latest Viridian Therapeutics' Other Current Assets Growth Pattern
Below is the plot of the Other Current Assets of Viridian Therapeutics over the last few years. It is assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories. Viridian Therapeutics' Other Current Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Viridian Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Other Current Assets | 10 Years Trend |
|
Other Current Assets |
| Timeline |
Viridian Other Current Assets Regression Statistics
| Arithmetic Mean | 2,665,836 | |
| Geometric Mean | 1,014,316 | |
| Coefficient Of Variation | 119.96 | |
| Mean Deviation | 2,358,859 | |
| Median | 1,972,000 | |
| Standard Deviation | 3,198,022 | |
| Sample Variance | 10.2T | |
| Range | 9.3M | |
| R-Value | 0.86 | |
| Mean Square Error | 2.9T | |
| R-Squared | 0.74 | |
| Significance | 0.000039 | |
| Slope | 615,058 | |
| Total Sum of Squares | 143.2T |
Viridian Other Current Assets History
About Viridian Therapeutics Financial Statements
Viridian Therapeutics investors utilize fundamental indicators, such as Other Current Assets, to predict how Viridian Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Other Current Assets | 9 M | 9.5 M |
Pair Trading with Viridian Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Viridian Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Viridian Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Viridian Stock
| 0.8 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.79 | FLGC | Flora Growth Corp | PairCorr |
| 0.72 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
Moving against Viridian Stock
| 0.91 | ERNA | Eterna Therapeutics | PairCorr |
| 0.88 | VALN | Valneva SE ADR | PairCorr |
| 0.83 | SNSE | Sensei Biotherapeutics | PairCorr |
| 0.79 | MOLN | Molecular Partners | PairCorr |
| 0.77 | NXTC | NextCure | PairCorr |
The ability to find closely correlated positions to Viridian Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Viridian Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Viridian Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Viridian Therapeutics to buy it.
The correlation of Viridian Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Viridian Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Viridian Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Viridian Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Viridian Therapeutics Correlation against competitors. To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viridian Therapeutics. If investors know Viridian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viridian Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.25) | Revenue Per Share 0.005 | Return On Assets (0.33) | Return On Equity (0.54) |
The market value of Viridian Therapeutics is measured differently than its book value, which is the value of Viridian that is recorded on the company's balance sheet. Investors also form their own opinion of Viridian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Viridian Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viridian Therapeutics' market value can be influenced by many factors that don't directly affect Viridian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Viridian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Viridian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viridian Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.